Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.76
(-1.43%)
CAD 2.76
(-1.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 59.51 Million USD | -0.87% |
| 2022 | 60.03 Million USD | 58.3% |
| 2021 | 37.92 Million USD | -9.71% |
| 2020 | 42 Million USD | 42.67% |
| 2019 | 29.44 Million CAD | 96.5% |
| 2018 | 14.98 Million CAD | 283.79% |
| 2017 | 3.9 Million CAD | 51.84% |
| 2016 | 2.57 Million CAD | 35.98% |
| 2015 | 1.89 Million CAD | -48.8% |
| 2014 | 3.69 Million CAD | 20.34% |
| 2013 | 3.06 Million CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 14.83 Million USD | 11.5% |
| 2023 Q4 | 13.3 Million USD | 4.82% |
| 2023 Q3 | 12.69 Million USD | -22.02% |
| 2023 Q2 | 16.27 Million USD | -5.57% |
| 2023 Q1 | 17.23 Million USD | 14.79% |
| 2023 FY | 59.51 Million USD | -0.87% |
| 2022 Q1 | 12.94 Million USD | 27.98% |
| 2022 Q2 | 16.14 Million USD | 24.72% |
| 2022 Q3 | 15.93 Million USD | -1.31% |
| 2022 Q4 | 15.01 Million USD | -5.75% |
| 2022 FY | 60.03 Million USD | 58.3% |
| 2021 FY | 37.92 Million USD | -9.71% |
| 2021 Q2 | 9.38 Million USD | 35.59% |
| 2021 Q3 | 11.5 Million USD | 22.51% |
| 2021 Q1 | 6.92 Million USD | -5.44% |
| 2021 Q4 | 10.11 Million USD | -12.06% |
| 2020 Q3 | 12.87 Million CAD | 34.16% |
| 2020 Q4 | 7.32 Million USD | -43.13% |
| 2020 Q2 | 9.59 Million CAD | -12.41% |
| 2020 Q1 | 10.95 Million CAD | 43.38% |
| 2020 FY | 42 Million USD | 42.67% |
| 2019 Q1 | 7.54 Million CAD | 30.68% |
| 2019 Q3 | 6.86 Million CAD | -5.34% |
| 2019 Q2 | 7.25 Million CAD | -3.85% |
| 2019 FY | 29.44 Million CAD | 96.5% |
| 2019 Q4 | 7.64 Million CAD | 11.28% |
| 2018 Q1 | 1.32 Million CAD | 128.17% |
| 2018 Q4 | 5.77 Million CAD | -12.15% |
| 2018 FY | 14.98 Million CAD | 283.79% |
| 2018 Q3 | 6.57 Million CAD | 357.64% |
| 2018 Q2 | 1.43 Million CAD | 8.67% |
| 2017 Q1 | 989.61 Thousand CAD | 79.89% |
| 2017 Q3 | 937.29 Thousand CAD | -32.21% |
| 2017 Q4 | 579.17 Thousand CAD | -38.21% |
| 2017 FY | 3.9 Million CAD | 51.84% |
| 2017 Q2 | 1.38 Million CAD | 39.72% |
| 2016 Q2 | 928.63 Thousand CAD | 99.06% |
| 2016 FY | 2.57 Million CAD | 35.98% |
| 2016 Q1 | 466.5 Thousand CAD | 10.44% |
| 2016 Q4 | 550.13 Thousand CAD | -17.09% |
| 2016 Q3 | 663.56 Thousand CAD | -28.54% |
| 2015 FY | 1.89 Million CAD | -48.8% |
| 2015 Q4 | 422.41 Thousand CAD | -14.97% |
| 2015 Q3 | 496.76 Thousand CAD | -30.13% |
| 2015 Q2 | 710.97 Thousand CAD | 45.72% |
| 2015 Q1 | 487.9 Thousand CAD | -63.72% |
| 2014 Q1 | 829.75 Thousand CAD | 0.0% |
| 2014 FY | 3.69 Million CAD | 20.34% |
| 2014 Q4 | 1.34 Million CAD | 69.99% |
| 2014 Q2 | 831.63 Thousand CAD | 0.23% |
| 2014 Q3 | 791.23 Thousand CAD | -4.86% |
| 2013 Q3 | 1.16 Million CAD | 0.0% |
| 2013 FY | 3.06 Million CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | -100.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q3 | 573.91 Thousand CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aurora Cannabis Inc. | 131.46 Million CAD | 54.728% |
| Avicanna Inc. | 6.65 Million CAD | -793.779% |
| Avant Brands Inc. | 12.43 Million CAD | -378.716% |
| Cardiol Therapeutics Inc. | -248.35 Thousand CAD | 24063.278% |
| Crescita Therapeutics Inc. | 10.36 Million CAD | -474.238% |
| Knight Therapeutics Inc. | 152.65 Million CAD | 61.013% |
| MediPharm Labs Corp. | 5.85 Million CAD | -916.465% |
| OrganiGram Holdings Inc. | 35.07 Million CAD | -69.685% |
| Canopy Growth Corporation | 80.88 Million CAD | 26.419% |
| Willow Biosciences Inc. | -659 Thousand CAD | 9130.956% |
| Auxly Cannabis Group Inc. | 21.27 Million CAD | -179.71% |